Axogen Q2 2025 revenue $56.7M (+18.3% YoY); raises FY guidance to $219M

Axogen, Inc.

2025-Q2 EPS reported -$0.07 revenue$105,222,000

Q2 revenue $56.7M (+18.3% YoY); net income $0.6M ($0.01 EPS) vs loss of $1.9M ($0.04) year ago.
Adjusted EPS $0.12 vs $0.05 YoY; adjusted EBITDA $9.3M vs $5.6M; gross margin 74.2% up from 73.8%.
Raised FY25 revenue guidance to at least 17% growth, or $219M; reiterates gross margin 73-75% and net cash flow positive.
FDA accepted BLA for Avance Nerve Graft; PDUFA date Sept 5, 2025; pre-licensing inspection and regulatory milestones completed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.